In an effort to provide more timely review of core prescription drug launch materials, the US Food and Drug Administration is adding a five-day screening period to the review process to make sure companies have submitted the appropriate information.
Susannah O’Donnell, review team leader in the Office of Prescription Drug Promotion, explained in a webinar that during the screening period, the agency will confirm that a submission is complete and consists of core